98%
921
2 minutes
20
In the rising and frail head and neck cancer (HNC) population, geriatric assessments are crucial. Frail HNC patients often experience dysphagia. The coexistence of dysphagia and frailty presents complex health challenges, however, there is limited evidence on the prognostic value of frailty on post-treatment dysphagia. This study explores the relationship between pre-treatment frailty status and post-treatment dysphagia in HNC patients. A retrospective data analysis from the OncoLifeS data-biobank at the University Medical Center Groningen of 242 patients diagnosed with HNC between 2014 and 2016. The study involved several physical, functional and psychological pre-treatment geriatric assessments, and frailty screening using the Groningen Frailty Indicator (GFI) and the Geriatric-8 screening tool (G8). Outcome measures were swallowing-related quality of life (HNSW-QoL) and toxicity-related dysphagia evaluations (CTCAE-D) at 3, 6, 12 and 24 months. Linear mixed-effects models assessed factors associated with HNSW-QoL and CTCAE-D. Frail patients consistently reported worse HNSW-QoL and CTCAE-D than non-frail patients over time, with symptoms increasing at 3 months, but gradually decreasing by 24 months. Frailty status (G8 or GFI) was a significant predictor for lower HNSW-QoL (β = 11.770 and 10.936, both p < 0.001), and lower CTCAE-D (β = 0.245, p = 0.058; β = 0.331, p = 0.019), respectively. In this study, frailty was found to be associated with a worse of swallowing-related quality of life, and with increased toxicity-related dysphagia. These findings provide insights for the identification of HNC patients at higher risk of post-treatment swallowing-related issues, and offer opportunities for optimizing their post-treatment swallowing outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145293 | PMC |
http://dx.doi.org/10.1007/s00455-024-10754-7 | DOI Listing |
Introduction: The combination of 3D radiation therapy (3D-RT) with cisplatin has been the conventional treatment for squamous cell carcinoma of the head and neck for decades.
Aims: To assess the impact of 3D radiotherapy with cisplatin on the Eastern Cooperative Oncology Group (ECOG) performance status and quality of life in terms of acute side effects among head and neck cancer patients.
Methodology: After obtaining the hospital's ethical approval, 106 head and neck cancer patients were enrolled at the Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.
J Voice
September 2025
Department of Otolaryngology - Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.
Objective: To investigate the potential relationship between retrograde cricopharyngeal dysfunction (R-CPD) and laryngopharyngeal reflux disease (LPRD) at baseline and whether cricopharyngeal sphincter paralysis botulinum toxin injection (BTI) is associated with an increase of LPRD symptoms in treated R-CPD patients.
Methods: Patients with clinical diagnosis of R-CPD were prospectively recruited from two European hospitals. Controls included individuals unable to burp without troublesome symptoms (CT1) and healthy subjects able to burp (CT2).
Laryngoscope
September 2025
Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.
Objective: In head and neck cancer (HNC) survivors not actively receiving dysphagia care, long-term dysphagia prevalence, dysphagia-related complications, and quality of life outcomes remain poorly understood. Understanding these outcomes is critical for creating effective HNC survivorship programs.
Methods: HNC survivors who completed cancer treatment > 2 years prior who had not undergone a swallow evaluation or therapy for > 1 year completed the MD Anderson Dysphagia Inventory (MDADI) and reported dysphagia-related complications.
Radiother Oncol
August 2025
Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Introduction: We present the first-in-human application of stereotactic radiosurgery (SRS) targeting the left stellate ganglion (LSG) as a non-invasive neuromodulatory strategy for treating polymorphic ventricular tachycardia/ventricular fibrillation (VT/VF).
Materials And Methods: A 69-year-old man with mixed-etiology cardiomyopathy (LVEF 28 %) experienced 27 VT/VF episodes over three months. This resulted in 18 implantable cardioverter-defibrillator (ICD) shocks and nine anti-tachycardia pacing therapies, despite optimal pharmacotherapy, catheter ablation and two temporary LSG blocks.
Curr Oncol
June 2025
Department 12-Otorhynolaryngology, Ophthalmology, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
: Quality of life (QoL) is a critical indicator in assessing the success of oncological treatments for head and neck malignancies, reflecting their impact on physiological functions and psychosocial well-being beyond mere survival. Treatments (surgery, radiotherapy, chemotherapy) pose multiple functional and emotional challenges, and recent advancements underscore the necessity of evaluating post-treatment QoL. : This literature review investigates the impact of oncological treatment on the QoL of patients with malignant head and neck cancers (oral, oropharyngeal, hypopharyngeal, laryngeal) and identifies factors influencing their QoL index.
View Article and Find Full Text PDF